September 6, 2025 • 4 mins
Welcome back to Ozempic Weightloss Unlocked, the podcast dedicated to bringing you the latest news, updates, and insights on Ozempic and its impact on weight, health, and lifestyle.
Today, we start with the basics: Ozempic is a medication based on semaglutide, and it is part of a class of drugs called GLP-1 receptor agonists. These drugs work by mimicking a hormone in your gut that helps regulate blood sugar and appetite. According to Purdue University, after a meal, the body naturally releases GLP-1, which helps stimulate insulin production and signals the brain to feel full. Ozempic uses a modified version of this hormone, which not only lowers blood sugar but also reduces appetite, leading to significant weight loss. Clinical studies suggest people can lose between five and twelve percent of their body weight, while also seeing improvements in blood sugar and cardiovascular health.
Ozempic is recommended as the first injectable therapy for diabetes by the American Diabetes Association, but most of its headline-grabbing popularity now comes from its off-label use for weight loss. Over fifteen million adults in the United States now use medications like Ozempic, Wegovy, or similar GLP-1-based drugs. The Wall Street Journal reports that this number has been climbing steadily each year.
But as more people turn to Ozempic, new challenges and concerns are emerging. The most common side effects are nausea and digestive issues, which can be so severe that up to forty percent of people stop using the drug within the first month, according to Tufts University researchers. Even for those who tolerate Ozempic, there are drawbacks. Experts at Purdue University caution that weight often returns when the drug is discontinued, meaning it is not a permanent fix. Other concerns are rising as well. Mass General Brigham recently published research in JAMA Ophthalmology that links semaglutide to a greater risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden, permanent blindness. People with diabetes taking semaglutide were over four times more likely to develop this disorder than those who did not.
At the same time, there is a lot of online buzz around microdosing, or taking very small amounts of GLP-1 drugs for longevity or anti-aging. The Washington Post and The Independent have both reported that leading experts see no solid scientific evidence that microdosing these drugs provides any benefit or is even safe. Companies marketing microdosing protocols are ahead of the actual science.
Researchers at Tufts are now developing new medications that target even more hormone receptors, hoping to be more effective, easier to take, and come with fewer side effects. Their most recent breakthrough aims for a four-in-one drug that tackles multiple hormones tied to metabolism and appetite, with the goal of delivering even greater and longer-lasting weight loss. The hope is that future drugs could treat obesity and simultaneously reduce risks for over one hundred eighty diseases linked to excess weight, including diabetes, cancer, and heart disease.
Meanwhile, there are also efforts to stimulate the body’s own GLP-1 production naturally, possibly through dietary fibers or future supplements. Purdue researchers believe this could help people maintain weight loss after coming off Ozempic, without the harsh side effects of injections, though results so far show milder weight control than with the actual drug.
To sum up, Ozempic has opened a new chapter in metabolic medicine, but there are still risks, unanswered questions, and an ever-changing landscape as science races forward. We will be here to keep you informed with the latest evidence and expert insights.
Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe so you do not miss our future updates and expert interviews. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Today, we start with the basics: Ozempic is a medication based on semaglutide, and it is part of a class of drugs called GLP-1 receptor agonists. These drugs work by mimicking a hormone in your gut that helps regulate blood sugar and appetite. According to Purdue University, after a meal, the body naturally releases GLP-1, which helps stimulate insulin production and signals the brain to feel full. Ozempic uses a modified version of this hormone, which not only lowers blood sugar but also reduces appetite, leading to significant weight loss. Clinical studies suggest people can lose between five and twelve percent of their body weight, while also seeing improvements in blood sugar and cardiovascular health.
Ozempic is recommended as the first injectable therapy for diabetes by the American Diabetes Association, but most of its headline-grabbing popularity now comes from its off-label use for weight loss. Over fifteen million adults in the United States now use medications like Ozempic, Wegovy, or similar GLP-1-based drugs. The Wall Street Journal reports that this number has been climbing steadily each year.
But as more people turn to Ozempic, new challenges and concerns are emerging. The most common side effects are nausea and digestive issues, which can be so severe that up to forty percent of people stop using the drug within the first month, according to Tufts University researchers. Even for those who tolerate Ozempic, there are drawbacks. Experts at Purdue University caution that weight often returns when the drug is discontinued, meaning it is not a permanent fix. Other concerns are rising as well. Mass General Brigham recently published research in JAMA Ophthalmology that links semaglutide to a greater risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden, permanent blindness. People with diabetes taking semaglutide were over four times more likely to develop this disorder than those who did not.
At the same time, there is a lot of online buzz around microdosing, or taking very small amounts of GLP-1 drugs for longevity or anti-aging. The Washington Post and The Independent have both reported that leading experts see no solid scientific evidence that microdosing these drugs provides any benefit or is even safe. Companies marketing microdosing protocols are ahead of the actual science.
Researchers at Tufts are now developing new medications that target even more hormone receptors, hoping to be more effective, easier to take, and come with fewer side effects. Their most recent breakthrough aims for a four-in-one drug that tackles multiple hormones tied to metabolism and appetite, with the goal of delivering even greater and longer-lasting weight loss. The hope is that future drugs could treat obesity and simultaneously reduce risks for over one hundred eighty diseases linked to excess weight, including diabetes, cancer, and heart disease.
Meanwhile, there are also efforts to stimulate the body’s own GLP-1 production naturally, possibly through dietary fibers or future supplements. Purdue researchers believe this could help people maintain weight loss after coming off Ozempic, without the harsh side effects of injections, though results so far show milder weight control than with the actual drug.
To sum up, Ozempic has opened a new chapter in metabolic medicine, but there are still risks, unanswered questions, and an ever-changing landscape as science races forward. We will be here to keep you informed with the latest evidence and expert insights.
Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe so you do not miss our future updates and expert interviews. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome back to a Zenpic weight Loss Unlocked, the podcast
dedicated to bringing you the latest news, updates, and insights
on a zepic and its impact on weight, health and lifestyle.
Today we start with the basics. A Zepic is a
medication based on semaglutide, and it is part of a
class of drugs called GLP one receptor agonists. These drugs
(00:20):
work by mimicking a hormone in your gut that helps
regulate blood sugar and appetite. According to Purdue University, after
a meal, the body naturally releases GLP one, which helps
stimulate insulin production and signals the brain to feel full.
Ozepic uses a modified version of this hormone, which not
only lowers blood sugar but also reduces appetite, leading to
(00:42):
significant weight loss. Clinical studies suggest people can lose between
five and twelve percent of their body weight while also
seeing improvements in blood sugar and cardiovascular health. Ozenpic is
recommended as the first injectable therapy for diabetes by the
American Diabetes Association, but most of its headline grabbing popularity
now comes from its off label use for weight loss.
(01:05):
Over fifteen million adults in the United States now use
medications like ozempic, wagovi, or similar GLP one based drugs.
The Wall Street Journal reports that this number has been
climbing steadily each year, but as more people turn to ozempic,
new challenges and concerns are emerging. The most common side
effects are nausea and digestive issues, which can be so
(01:27):
severe that up to forty percent of people stop using
the drug within the first month, according to Tuss University researchers.
Even for those who tolerate ozempic, there are drawbacks. Experts
at Purdue University caution that weight often returns when the
drug is discontinued, meaning it is not a permanent fix.
Other concerns are rising as well. Mass General Brigham recently
(01:51):
published research in Jamma Ophthalmology that links semaglutide to a
greater risk of non arteritic anterior ischemic optic neuropthy an
addition that can cause sudden permanent blindness. People with diabetes
taking semaglutide were over four times more likely to develop
this disorder than those who did not. At the same time,
(02:12):
there is a lot of online buzz around microdosing, or
taking very small amounts of GLP one drugs for longevity
or anti aging. The Washington Post and The Independent have
both reported that leading experts see no solid scientific evidence
that microdosing these drugs provides any benefit or as even safe.
(02:33):
Companies marketing microdosing protocols are ahead of the actual science.
Researchers at Tufts are now developing new medications that target
even more hormone receptors, hoping to be more effective, easier
to take, and come with fewer side effects. Their most
recent breakthrough aims for a four in one drug that
tackles multiple hormones tied to metabolism and appetite, with the
(02:56):
goal of delivering even greater and longer lasting weight life.
The hope is that future drugs could treat obesity and
simultaneously reduce risks for over one hundred and eighty diseases
linked to excess weight, including diabetes, cancer, and heart disease. Meanwhile,
there are also efforts to stimulate the body's own GLP
(03:17):
ie production naturally, possibly through dietary fibers or future supplements.
Perdue researches believe this could help people maintain weight loss
after coming off as zepic without the harsh side effects
of injections, though results so far show milder weight control
than with the actual drug to sum up. Azempic has
opened a new chapter in metabolic medicine, but there are
(03:39):
still risks, unanswered questions, and an ever changing landscape. As
science races forward, we will be here to keep you
informed with the latest evidence and expert insights. Thank you
for tuning in to Azempic Weight Loss U LOT. If
you found this episode helpful, please subscribe so you do
not miss off few updates and expert interviews. This has
(04:02):
been a quiet please production. For more check out quite
please dot ai
Welcome back to a Zenpic weight Loss Unlocked, the podcast
dedicated to bringing you the latest news, updates, and insights
on a zepic and its impact on weight, health and lifestyle.
Today we start with the basics. A Zepic is a
medication based on semaglutide, and it is part of a
class of drugs called GLP one receptor agonists. These drugs
(00:20):
work by mimicking a hormone in your gut that helps
regulate blood sugar and appetite. According to Purdue University, after
a meal, the body naturally releases GLP one, which helps
stimulate insulin production and signals the brain to feel full.
Ozepic uses a modified version of this hormone, which not
only lowers blood sugar but also reduces appetite, leading to
(00:42):
significant weight loss. Clinical studies suggest people can lose between
five and twelve percent of their body weight while also
seeing improvements in blood sugar and cardiovascular health. Ozenpic is
recommended as the first injectable therapy for diabetes by the
American Diabetes Association, but most of its headline grabbing popularity
now comes from its off label use for weight loss.
(01:05):
Over fifteen million adults in the United States now use
medications like ozempic, wagovi, or similar GLP one based drugs.
The Wall Street Journal reports that this number has been
climbing steadily each year, but as more people turn to ozempic,
new challenges and concerns are emerging. The most common side
effects are nausea and digestive issues, which can be so
(01:27):
severe that up to forty percent of people stop using
the drug within the first month, according to Tuss University researchers.
Even for those who tolerate ozempic, there are drawbacks. Experts
at Purdue University caution that weight often returns when the
drug is discontinued, meaning it is not a permanent fix.
Other concerns are rising as well. Mass General Brigham recently
(01:51):
published research in Jamma Ophthalmology that links semaglutide to a
greater risk of non arteritic anterior ischemic optic neuropthy an
addition that can cause sudden permanent blindness. People with diabetes
taking semaglutide were over four times more likely to develop
this disorder than those who did not. At the same time,
(02:12):
there is a lot of online buzz around microdosing, or
taking very small amounts of GLP one drugs for longevity
or anti aging. The Washington Post and The Independent have
both reported that leading experts see no solid scientific evidence
that microdosing these drugs provides any benefit or as even safe.
(02:33):
Companies marketing microdosing protocols are ahead of the actual science.
Researchers at Tufts are now developing new medications that target
even more hormone receptors, hoping to be more effective, easier
to take, and come with fewer side effects. Their most
recent breakthrough aims for a four in one drug that
tackles multiple hormones tied to metabolism and appetite, with the
(02:56):
goal of delivering even greater and longer lasting weight life.
The hope is that future drugs could treat obesity and
simultaneously reduce risks for over one hundred and eighty diseases
linked to excess weight, including diabetes, cancer, and heart disease. Meanwhile,
there are also efforts to stimulate the body's own GLP
(03:17):
ie production naturally, possibly through dietary fibers or future supplements.
Perdue researches believe this could help people maintain weight loss
after coming off as zepic without the harsh side effects
of injections, though results so far show milder weight control
than with the actual drug to sum up. Azempic has
opened a new chapter in metabolic medicine, but there are
(03:39):
still risks, unanswered questions, and an ever changing landscape. As
science races forward, we will be here to keep you
informed with the latest evidence and expert insights. Thank you
for tuning in to Azempic Weight Loss U LOT. If
you found this episode helpful, please subscribe so you do
not miss off few updates and expert interviews. This has
(04:02):
been a quiet please production. For more check out quite
please dot ai
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Cardiac Cowboys
The heart was always off-limits to surgeons. Cutting into it spelled instant death for the patient. That is, until a ragtag group of doctors scattered across the Midwest and Texas decided to throw out the rule book. Working in makeshift laboratories and home garages, using medical devices made from scavenged machine parts and beer tubes, these men and women invented the field of open heart surgery. Odds are, someone you know is alive because of them. So why has history left them behind? Presented by Chris Pine, CARDIAC COWBOYS tells the gripping true story behind the birth of heart surgery, and the young, Greatest Generation doctors who made it happen. For years, they competed and feuded, racing to be the first, the best, and the most prolific. Some appeared on the cover of Time Magazine, operated on kings and advised presidents. Others ended up disgraced, penniless, and convicted of felonies. Together, they ignited a revolution in medicine, and changed the world.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.